Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

Listing of Claims

1-17. **(Canceled)**

18. **(Original)** A pharmacologically active compound of formula (I)

$$Y(W_u,V_z,X_r,A_k) \qquad (I)$$

wherein

Y represents the molecular moiety of formula (Ia),



(Ia)

wherein n is an integer from 10 to 400; one of R_1 and R_2 represents hydrogen atom whereas the other one represents a group of formula (B);



(B)

R_3 represents a polymerization-initiating group;

W represents a hydroxyl group, optionally as a salt formed with an alkali metal ion;

V represents a C1-8 alkylamino group bonded through its amino group or a valence bond;

X is a "spacer" group being an amino acid group or an oligopeptide group of at most six members wherein the amino acid or oligopeptide group is coupled through its N-terminal to the Y group and

is optionally bearing a hydroxyl group or a valence bond on its C-terminal, wherein the amino acids are Gly, Ala, Leu, Ile, Val, Phe, Tyr, Ahx, Pro, Arg, or His;

A is present and represents a pharmacologically active polypeptide hormone group containing an amino group and directly coupled therethrough to the Y group when r is 0; or coupled to the C-terminal of the X group, respectively, when r is larger than 0;

r is an integer from 0 to 0.2 n;

k is an integer being at most equal to r; z is an integer from 0 to (n-r); and

u is an integer from n to 2n-r-z, as well as the salts and complexes of these compounds.

19. (**Original**) The pharmacologically active compound of formula (I) of claim 18, wherein R_3 is a $(CH_3)_2CCN$ group.

20. (**Original**) The pharmacologically active compound of formula (I) of claim 19, wherein:

A represents a native gonadotropin-releasing hormone (GnRH) coupled through its amino group or a pharmacologically active analogue thereof; and k, r, u, z, X, Y, V and W are as defined in claim 18, as well as the salts and complexes of these compounds.

21. (**Original**) The pharmacologically active compound of formula (I) of claim 20, wherein

A represents

pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH_2 (SEQ ID NO:2),

Ac-D-$Trp^{1,3}$, p-chlorophenyl-D-alanine^2(D-Cpa^2),D-Lys^6,D-Ala^{10}-gonadotropin-releasing hormone (GnRH)

Ac-D-$Trp^{1,3}$, D-Cpa^2,Lys^5,[Asp(a-DEA)]^6,D-Ala^{10}-Gln^8-GnRH,

D-Phe^2,D-Trp^3,D-Lys^6-GnRH,

Lys^5,cyclo(Asp^6-Lys^8)-GnRH-III,

Lys^4,[Lys(ε-Fmoc)]^8-GnRH-III,

Lys^4-GnRH-III,

D-Lys^6-GnRH,

Lys^5,D-Trp^6-GnRH

coupled to X or Y through the ε-amino group of their Lys side chains; and k, r, u, z, X, Y, V and W are as defined in claim 18, as well as the salts and complexes of these compounds.

22. **(Original)** The pharmacologically active compound of formula (I) of claim 18, wherein X represents an oligopeptide group consisting of four members; and k, r, u, z, A, Y, V and W are as defined in claim 18, as well as the salts and complexes of these compounds.

23. **(Original)** The pharmacologically active compound of formula (I) of claim 18, wherein X represents an oligopeptide group consisting of three members; and k, r, u, z, A, Y, V and W are as defined in claim 18, as well as the salts and complexes of these compounds.

24. **(Original)** The pharmacologically active compound of formula (I) of claim 18, wherein V is a C4-6 alkylamino group.

25. **(Original)** The pharmacologically active compound of formula (I) of claim 18, wherein r is 0; and k, u, z, A, Y, V and W are as defined in claim 18, as well as the salts and complexes of these compounds.

26. **(Original)** A compound containing an activated ester group of formula (Ic),

$$Y[W_u,V'_z,(XOQ)_r] \qquad (Ic)$$

wherein Y represents the molecular moiety of formula (Ia), wherein n is an integer from 10 to 400; one of R_1 and R_2 represents hydrogen atom whereas the other one represents a group of formula (B); R_3 represents a polymerization-initiating group; W represents a hydroxyl group, optionally as a salt formed with an alkali metal ion; V' represents a C1-8, alkylamino group bonded through its amino group; X represents an amino acid group or an oligopeptide group of at most six members coupled through its N-terminal to the Y group; OQ represents an activated ester group on C-terminal of the X group; r is an integer from 0 to 0.2 n; z is an integer from 0 to (n-r); and u is an integer from n to (2n-r-z), as well as the salts of these compounds.

27. **(Original)** Compounds of formula (Ic) as claimed in claim 26, wherein X represents an oligopeptide group consisting of at most four members, preferably -Gly-Phe-Leu-Gly-, -Gly-Phe-Gly-, -Phe-Leu- Gly- or -Ahx-; OQ represents ONp group; and k, r, u, z, A, Y, V' as well as W are as defined in claim 26, as well as the salts of these compounds.

28. **(Original)** A pharmaceutical composition comprising a compound of formula (I) of claim 18, wherein k. r, u, z, X, Y, V and W are as defined in claim 18, or a pharmaceutically acceptable salt or complex thereof in admixture with carriers and/or additives commonly used in the pharmaceutical industry.

29. **(Original)** A tumour-inhibiting pharmaceutical composition comprising a compound of formula (I) of claim 20 or a pharmaceutically acceptable salt or complex thereof in admixture with carriers and/or additives commonly used in the pharmaceutical industry.

30. **(Original)** A tumour-inhibiting and immunostimulatory pharmaceutical composition comprising a compound of formula (I), wherein A represents Ac-D-$Trp^{1,3}$, p-chlorophenyl-D-$alanine^{2}$(D-Cpa^{2}),Lys^{5},[Asp(a-DEA)]^{6},D-Ala^{10}-Gln^{8}-GnRH, and k, r, z, u, X, Y, V and W are as defined in claim 18, or a pharmaceutically acceptable salt or complex thereof in admixture with carriers and/or additives commonly used in the pharmaceutical industry.

31. **(Original)** A composition comprising a compound of claim 18 in combination with a pharmaceutically acceptable carrier.

32. **(Original)** The pharmacologically active compound of claim 18, wherein n is an integer from 20 to 200.

33. **(Original)** The pharmacologically active compound of claim 22, wherein X represents -Gly-Phe-Leu-Gly- (SEQ ID NO:5).

34. **(Original)** The pharmacologically active compound of claim 23, wherein X represents -Phe-Leu-Gly-.

35. **(Original)** The pharmacologically active compound of claim 23, wherein X represents -Gly-Leu-Gly-.

36. **(Original)** The compound of claim 26, wherein n is an integer from 20 to 200.

37. **(Original)** The compound of claim 26, wherein R_3 represents $(CH_3)_2CCN$.

38. **(Original)** The compound of claim 26, wherein W represents a hydroxyl grop as a salt formed with a sodium ion.

39. **(Original)** The compound of claim 26, wherein V' represents a C4-6 alkylamino group.

40. **(Original)** The compound of claim 26, wherein the activated ester group is selected from the group consisting of ONp, OPcp, Opfp, and ONsu.

41. **(Original)** A tumour-inhibiting pharmaceutical composition comprising a compound of formula (I) of claim 21 or a pharmaceutically acceptable salt or complex thereof in admixture with carriers and/or additives commonly used in the pharmaceutical industry.